Gastrin

What is Gastrin?

Gastrin is an endogenous peptide hormone of the upper gastrointestinal tract — the principal humoral driver of gastric acid secretion and one of the founding members of the gut-hormone field. It is produced by G cells of the pyloric antrum (and to a lesser extent the duodenum) as a 101-amino-acid preprogastrin precursor, which is processed to two main bioactive forms: little gastrin (G17, 17 amino acids) and big gastrin (G34, 34 amino acids). Both forms share the C-terminal Trp-Met-Asp-Phe-NH2 (WMDF-amide) tetrapeptide that constitutes the receptor-binding pharmacophore — a sequence that is identical to the C-terminal pharmacophore of cholecystokinin (CCK), reflecting their common ancestral gene. A sulfated tyrosine seven residues from the C-terminus distinguishes G17 II (sulfated) from G17 I (non-sulfated); both circulate in human plasma. Gastrin signals through the CCK-2 receptor (CCKBR, also called CCK-B or gastrin receptor), a Gq-coupled GPCR cloned by Wank, Kopin, and colleagues in the early 1990s. The receptor is expressed primarily on enterochromaffin-like (ECL) cells of the oxyntic mucosa — where gastrin triggers histamine release that drives parietal-cell acid secretion — and on parietal cells themselves, where direct signaling supplements the indirect ECL-mediated pathway. Gastrin is also strongly trophic to the oxyntic mucosa, increasing ECL-cell number and parietal-cell mass during sustained hypergastrinemia. The functional discovery is credited to John Edkins (1905), who proposed an antral 'gastric secretin' on indirect physiological grounds, and the chemical structure was solved by Roderic Gregory and Hilda Tracy at Liverpool in 1964. Gastrin itself is not used therapeutically, but its synthetic C-terminal pentapeptide pentagastrin (Boc-β-Ala-Trp-Met-Asp-Phe-NH2) was for decades the standard agent in maximal-acid-secretion testing and pheochromocytoma/medullary-thyroid-carcinoma provocation tests. Clinically, gastrin biology is central to Zollinger-Ellison syndrome (gastrinoma), pernicious-anemia hypergastrinemia, proton-pump-inhibitor-induced hypergastrinemia, and the ECL-cell hyperplasia that arises when antral acid feedback on G-cell secretion is interrupted.

What Gastrin Is Investigated For

Gastrin is a textbook endocrine topic, not a peptide consumers take. The clinical conversations are diagnostic and pathophysiologic: serum gastrin is the central biomarker for Zollinger-Ellison syndrome, where a gastrinoma in the duodenum or pancreas drives uncontrolled acid hypersecretion, refractory peptic ulceration, and diarrhea; for autoimmune atrophic gastritis (pernicious anemia), where loss of parietal-cell acid output removes the antral feedback that normally restrains G cells, producing marked secondary hypergastrinemia and ECL-cell hyperplasia; and for proton-pump-inhibitor therapy, where pharmacologic acid suppression similarly drives a sustained, dose-dependent, reversible hypergastrinemia. The synthetic C-terminal pentapeptide pentagastrin was the workhorse of maximal-acid-output testing for decades and remains used in some settings as a provocation agent for medullary thyroid carcinoma and pheochromocytoma. Gastrin itself is not a therapeutic — it is studied as the endogenous hormone that governs the upper-GI acid-trophic axis and as a target of CCK-2 receptor antagonist drug development that, despite multiple clinical attempts (netazepide, itriglumide, others), has not yet produced an approved indication.

History & Discovery

Gastrin's history begins with John Sydney Edkins, a London physiologist who proposed in 1905 that the pyloric antrum of the stomach released a humoral factor — which he named 'gastric secretin' — that traveled via the bloodstream to stimulate acid secretion in the gastric body. The proposal was made on indirect physiological grounds (extracts of antral mucosa, when injected, produced acid secretion in test animals) and immediately attracted skeptical reception. For nearly half a century the hypothesis was disputed, the field unable to chemically isolate the proposed hormone, and many physiologists doubted its existence as a discrete entity. Edkins died in 1940 with the question unresolved. The vindication came from Roderic Alfred Gregory and Hilda Tracy at the University of Liverpool. Working from porcine antral mucosa and using a combination of column chromatography, countercurrent distribution, and rigorous bioassay, Gregory and Tracy purified gastrin to homogeneity and, in two 1964 papers in Gut, reported the 17-amino-acid sequence of little gastrin (G17) and the structure-activity relationships of the synthetic fragments. They identified the C-terminal Trp-Met-Asp-Phe-NH2 tetrapeptide as the bioactive pharmacophore — a sequence later recognized as identical to the C-terminus of cholecystokinin, reflecting the two hormones' descent from a common ancestral gene. Big gastrin (G34) was characterized later in the 1970s as a 34-amino-acid form predominant in fasting plasma and the duodenum. The synthetic C-terminal pentapeptide pentagastrin (Boc-β-Ala-Trp-Met-Asp-Phe-NH2), developed by Imperial Chemical Industries shortly after the Gregory-Tracy structural work, became the standard pharmacologic tool for maximal-acid-secretion testing and a workhorse of clinical gastric-function evaluation for decades. The receptor pharmacology was completed in the early 1990s when Kopin, Wank, Pisegna, and colleagues independently cloned the canine parietal-cell gastrin receptor and the human brain CCK-B receptor — the same molecule, now formally the CCK-2 receptor (CCKBR), shared with cholecystokinin. The clinical syndromes of gastrin excess emerged in parallel. Robert Zollinger and Edwin Ellison at Ohio State described in 1955 the syndrome of intractable peptic ulceration, severe acid hypersecretion, and non-beta-islet pancreatic tumors that now bears their names. Once gastrin radioimmunoassay was developed in the late 1960s, the gastrinoma origin of Zollinger-Ellison syndrome became biochemically demonstrable, and serum gastrin became one of the standard tumor biomarkers in clinical endocrinology. Pernicious anemia and atrophic gastritis were recognized as states of secondary hypergastrinemia driven by loss of antral acid feedback. The advent of H2 receptor antagonists in the 1970s and proton-pump inhibitors in the 1980s introduced pharmacologic hypergastrinemia as a chronic and very widely encountered finding — initially a source of intense oncologic concern when carcinoid tumors emerged in long-term-treated rats, ultimately reassessed as a largely benign reversible elevation in humans, though the trophic and rebound consequences continue to attract attention. Gastrin and CCK-2 receptor knockout mice (Friis-Hansen 1998; Langhans et al.) confirmed gastrin as the dominant trophic and secretory driver of the oxyntic mucosa, and the INS-GAS transgenic mouse from Wang, Fox, and colleagues (2000) anchored the gastrin-Helicobacter-cancer axis that underlies modern gastric-carcinogenesis research.

How It Works

Gastrin is a hormone made by special cells (G cells) in the stomach lining and upper small intestine. After you eat — especially a meal containing protein — these cells release gastrin into the bloodstream. Gastrin then circulates back to the stomach and tells the acid-producing cells to make more acid, which helps digest food. It does this in two ways: directly by signaling the parietal cells (the acid factories), and indirectly by triggering nearby ECL cells to release histamine, which then activates the parietal cells. Gastrin also acts as a growth signal for the stomach lining itself — when gastrin stays high for a long time (as in certain tumors or with long-term acid-blocker use), the stomach lining can thicken. Acid in the stomach normally tells the G cells to stop releasing gastrin — a feedback loop. When acid is missing (because of medications or autoimmune disease), the feedback breaks and gastrin levels rise.

Gastrin is encoded by the GAS gene on chromosome 17 in humans. The 101-amino-acid preprogastrin precursor undergoes signal-peptide cleavage and a series of post-translational processing steps in G cells of the antral and duodenal mucosa: endoproteolytic cleavage at dibasic sites by prohormone convertases PC1/3 and PC2, C-terminal trimming by carboxypeptidase E, and α-amidation of the C-terminal phenylalanine by peptidylglycine α-amidating monooxygenase (PAM). The major secreted forms are G17 (17 amino acids; predominant antral and postprandial-plasma form) and G34 (34 amino acids; predominant duodenal and fasting-plasma form). Both share the C-terminal Trp-Met-Asp-Phe-NH2 pharmacophore, identical to that of cholecystokinin. A sulfated tyrosine at position 6 from the C-terminus distinguishes G17 II (sulfated) from G17 I (non-sulfated); both circulate. Smaller and larger forms (G14, G52, progastrin, glycine-extended gastrin) circulate in lower abundance and have been investigated for separate signaling roles, particularly in colorectal proliferation. G-cell secretion is stimulated by luminal protein digestion products (aromatic and basic amino acids), gastric distension via vagal cholinergic and gastrin-releasing-peptide (GRP) pathways, and elevated intragastric pH. It is inhibited paracrinely by somatostatin from antral D cells, whose secretion is itself stimulated by low pH — establishing the central acid-feedback loop. Loss of acid output (atrophic gastritis, vagotomy, antisecretory drug therapy) lifts this feedback and produces secondary hypergastrinemia. Gastrin signals through the CCK-2 receptor (CCKBR, also called CCK-B or gastrin receptor), cloned by Wank and colleagues (canine parietal cell, 1992) and Pisegna and colleagues (human brain CCK-B/gastrin receptor, 1992). CCK-2 is a Gq-coupled GPCR with high affinity for both gastrin and CCK; the affinity difference is small enough that the two hormones are not pharmacologically separable at this receptor. CCK-2 activates phospholipase C, mobilizes intracellular calcium, and stimulates protein-kinase-C signaling. The principal effector circuit is gastrin → CCK-2 receptor on ECL cells → histamine release → H2 receptor on parietal cells → Gs/cAMP/PKA activation → assembly and trafficking of H+/K+-ATPase to the apical membrane → acid secretion. Gastrin also acts directly on parietal-cell CCK-2 receptors, providing a smaller cAMP-independent signal. Gastrin's trophic effects on the oxyntic mucosa — ECL hyperplasia and increased parietal-cell mass during chronic hypergastrinemia — are mediated by CCK-2 signaling in ECL cells with downstream ERK/MAPK activation. The INS-GAS transgenic mouse model from Wang, Fox, and colleagues (overexpressing amidated gastrin under the insulin promoter) demonstrated that chronic hypergastrinemia synergizes with Helicobacter infection to drive gastric atrophy and dysplasia, formalizing the link between gastrin and gastric carcinogenesis. Gastrin-deficient mice (Friis-Hansen and colleagues, 1998) develop achlorhydria with markedly reduced parietal- and ECL-cell numbers, confirming gastrin as the dominant trophic and secretory driver of the oxyntic mucosa.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Gastrin:

• 01The magnitude of gastric-cancer or ECL-derived neuroendocrine-tumor risk attributable to multi-decade proton-pump-inhibitor use in humans — a gastrin-mediated theoretical concern that has so far not translated into a clear epidemiologic signal but remains incompletely settled.
• 02The clinical viability of CCK-2 receptor antagonists (netazepide, others) for ECL-cell hyperplasia, gastrinoma, and acid-related disease — efficacy signals exist in early trials, but no agent has reached broad approval after multiple development attempts.
• 03The role of progastrin and glycine-extended gastrin (intermediate processing products) in colorectal-tumor biology — preclinical and observational signals suggest a proliferative role separate from amidated G17/G34 acting at CCK-2, but the human relevance remains unclear.
• 04Whether gastrin or pentagastrin provocation testing has remaining utility in 2026 endocrine practice given the availability of high-resolution imaging and improved tumor-marker assays.
• 05The reversibility timeline of PPI-induced ECL-cell hyperplasia and parietal-cell mass expansion in humans — relevant to PPI deprescribing strategies and rebound-symptom management.
• 06Whether selective inhibition of gastrin processing or gastrin-receptor signaling could modulate Helicobacter-driven gastric carcinogenesis in humans, given the strong INS-GAS mouse model evidence for the gastrin-Helicobacter synergy.

Forms & Administration

Gastrin is not formulated as a therapeutic in any jurisdiction. Synthetic gastrin and gastrin fragments are produced for research and reference-standard use. The synthetic C-terminal pentapeptide pentagastrin (Boc-β-Ala-Trp-Met-Asp-Phe-NH2) was historically marketed as a diagnostic agent for maximal-acid-output testing and remains used in some clinical settings as a provocation agent for medullary thyroid carcinoma and pheochromocytoma. Pentagastrin is administered subcutaneously or by intravenous infusion at standardized doses for these tests. CCK-2 receptor antagonists (netazepide and others) are investigational small molecules in clinical development for gastrin-driven disease. There is no consumer market, compounded preparation, or peptide-marketplace use case for gastrin or pentagastrin.

Common Questions

Who Gastrin Is NOT For

Drug & Supplement Interactions

Gastrin itself is not a drug, so direct drug-interaction profiles are limited to the diagnostic agent pentagastrin, which has no significant pharmacokinetic interactions but should be avoided with co-administration of other agents that strongly stimulate acid secretion or catecholamine release. The clinically important interactions in gastrin biology run in the other direction — drugs that perturb gastrin physiology. Proton-pump inhibitors (omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, dexlansoprazole) and H2 receptor antagonists (famotidine, ranitidine — withdrawn — cimetidine, nizatidine) all elevate serum gastrin in proportion to the magnitude of acid suppression, with PPIs producing the larger and more sustained effect. Atropine and other antimuscarinics reduce vagal cholinergic G-cell stimulation. Somatostatin and its long-acting analogs (octreotide, lanreotide, pasireotide) directly suppress G-cell gastrin secretion and are used therapeutically in gastrinoma. Glucocorticoids modestly stimulate gastrin secretion. The clinically important point for serum gastrin interpretation is that any patient on chronic acid-suppression therapy will have elevated levels for pharmacologic reasons, and gastrinoma evaluation typically requires PPI discontinuation (with specialist supervision) for valid assessment.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions